Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SB 007

Next Previous
Drug Profile

SB 007

Alternative Names: SB-007

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Splice Bio
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action ABCA4 protein modulators; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Stargardt disease

Most Recent Events

  • 11 Feb 2025 Phase-I/II clinical trials in Stargardt disease (In adolescent, In adults, In elderly) in USA (Subretinal) (NCT06942572)
  • 12 Dec 2024 SpliceBio plans a phase I/II ASTRA trial for Stargardt disease in the first half of 2025
  • 12 Dec 2024 US FDA approves IND application for SB 007 in Stargardt Disease

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top